China Net Finance, November 7th (Reporter Chen Qiong) On November 6th, Novo Nordisk held the launch ceremony of "Healthy China Action - Metabolic Renewal Year" at the Novo Nordisk booth at the 7th China International Import Expo. The launch of the "Healthy China Action - the first year of metabolism rejuvenation" aims to improve the public's awareness of metabolic diseases represented by diabetes and their prevention and control awareness, improve the health quality of the whole people, improve the healthy life quality of the whole people, and lay a solid foundation for promoting the construction of a healthy China.
In recent years, the incidence of metabolic diseases among Chinese residents has been increasing year by year, seriously endangering their health and becoming one of the important challenges facing public health. Novo Nordisk plans to support video and graphic science popularization projects, and invite authoritative experts to carry out mass science popularization education activities on metabolic health knowledge, so that the public can continuously understand the hazards of metabolic diseases, enhance their understanding of diseases, and contribute to the realization of "Healthy China 2030".
At present, China has the largest number of patients with diabetes in the world, accounting for more than a quarter of the world. There are about 140 million adults with diabetes in China [IDF Diabetes Atlas 10th edition 2021. Among them, the rate of reaching the standard of blood sugar in type 2 diabetes patients who only rely on oral hypoglycemic drugs is about one third. Nearly half of type 2 diabetes patients have abnormal blood lipids, and nearly 2/3 have hypertension. More seriously, there is a complex relationship between diabetes and multiple metabolic disorders. These metabolic abnormalities are intertwined and exacerbated together. Therefore, the social public science popularization of metabolic diseases represented by diabetes is imperative.
Zhou Xiaping, senior vice president of Novo Nordisk and president of Greater China, said: "As one of the most common metabolic disorders in the world, diabetes is expanding its scope of influence. For a century, Novo Nordisk, as a leader in the field of global diabetes treatment, has driven change, accelerated innovation, and constantly led the research and development of GLP-1 drugs. I am very happy to witness the official opening of the" Healthy China Action - the First Year of Healthy Metabolism Revitalization "with you, and discuss the comprehensive management of multiple metabolic disorders in patients with type 2 diabetes."
2024 marks the 30th year of the establishment of Novo Nordisk China, which has participated in the CIIE for seven consecutive years. Novo Nordisk has not only witnessed the accelerated landing and even simultaneous approval of numerous innovative drugs in China, completing the transformation from "exhibits" to "products", but also continuously exploring and innovating in public science education.